ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMGO Imago BioSciences Inc

36.01
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 37.82
Ask Price 34.21
News -
Company Name Stock Ticker Symbol Market Type
Imago BioSciences Inc IMGO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 36.01 20:00:00
Open Price Low Price High Price Close Price Prev Close
36.01 36.01
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 36.01 USD

Imago BioSciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.22B - - - -28.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Imago BioSciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IMGO Message Board. Create One! See More Posts on IMGO Message Board See More Message Board Posts

Historical IMGO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Imago BioSciences Description

Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).

Your Recent History

Delayed Upgrade Clock